Cargando…

The Epidemiology of COVID-19 and MS-Related Characteristics in a National Sample of People With MS in China

Few studies have focused on immune status and disease activity in MS patients during the coronavirus disease 2019 (COVID-19) pandemic. The aim of this study is to investigate immune status, COVID-19 infection, and attacks in MS patients during the pandemic. An online questionnaire about COVID-19 inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yao, Yin, Hexiang, Xu, Yan, Xu, Tao, Peng, Bin, Cui, Liying, Zhang, Shuyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193356/
https://www.ncbi.nlm.nih.gov/pubmed/34122322
http://dx.doi.org/10.3389/fneur.2021.682729
_version_ 1783706224105095168
author Zhang, Yao
Yin, Hexiang
Xu, Yan
Xu, Tao
Peng, Bin
Cui, Liying
Zhang, Shuyang
author_facet Zhang, Yao
Yin, Hexiang
Xu, Yan
Xu, Tao
Peng, Bin
Cui, Liying
Zhang, Shuyang
author_sort Zhang, Yao
collection PubMed
description Few studies have focused on immune status and disease activity in MS patients during the coronavirus disease 2019 (COVID-19) pandemic. The aim of this study is to investigate immune status, COVID-19 infection, and attacks in MS patients during the pandemic. An online questionnaire about COVID-19 infection, MS attack, and MS treatment during the pandemic was administered to all 525 MS patients registered in our hospital database from January 1, 2011, to June 1, 2020. Only 384 responded, of which 361 patients could be included in the final analysis. During the pandemic, 42.1% of the 361 patients and 65.0% of the 234 patients on immunotherapies were exposed to teriflunomide. Compared to patients who didn't receive treatment, patients exposed to DMTs had significantly lower levels of neutrophils (P < 0.01) and immunoglobulin G (P < 0.01), and patients exposed to immunosuppressants had significantly lower levels of immunoglobulin G (P < 0.05). Over 80% of our patients followed effective protective measures and none of the 361 MS patients in our cohort contracted COVID-19. Patients whose treatment was disrupted had a significantly higher annualized relapse rate (ARR) during than before the pandemic (P < 0.01), while the ARR of patients with continuous treatment or without treatment remained unchanged. During the pandemic, the risk of MS attack due to treatment disruption possibly outweighs the risk of COVID-19 infection under preventive measures, and MS treatment maintenance might be necessary.
format Online
Article
Text
id pubmed-8193356
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81933562021-06-12 The Epidemiology of COVID-19 and MS-Related Characteristics in a National Sample of People With MS in China Zhang, Yao Yin, Hexiang Xu, Yan Xu, Tao Peng, Bin Cui, Liying Zhang, Shuyang Front Neurol Neurology Few studies have focused on immune status and disease activity in MS patients during the coronavirus disease 2019 (COVID-19) pandemic. The aim of this study is to investigate immune status, COVID-19 infection, and attacks in MS patients during the pandemic. An online questionnaire about COVID-19 infection, MS attack, and MS treatment during the pandemic was administered to all 525 MS patients registered in our hospital database from January 1, 2011, to June 1, 2020. Only 384 responded, of which 361 patients could be included in the final analysis. During the pandemic, 42.1% of the 361 patients and 65.0% of the 234 patients on immunotherapies were exposed to teriflunomide. Compared to patients who didn't receive treatment, patients exposed to DMTs had significantly lower levels of neutrophils (P < 0.01) and immunoglobulin G (P < 0.01), and patients exposed to immunosuppressants had significantly lower levels of immunoglobulin G (P < 0.05). Over 80% of our patients followed effective protective measures and none of the 361 MS patients in our cohort contracted COVID-19. Patients whose treatment was disrupted had a significantly higher annualized relapse rate (ARR) during than before the pandemic (P < 0.01), while the ARR of patients with continuous treatment or without treatment remained unchanged. During the pandemic, the risk of MS attack due to treatment disruption possibly outweighs the risk of COVID-19 infection under preventive measures, and MS treatment maintenance might be necessary. Frontiers Media S.A. 2021-05-28 /pmc/articles/PMC8193356/ /pubmed/34122322 http://dx.doi.org/10.3389/fneur.2021.682729 Text en Copyright © 2021 Zhang, Yin, Xu, Xu, Peng, Cui and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Zhang, Yao
Yin, Hexiang
Xu, Yan
Xu, Tao
Peng, Bin
Cui, Liying
Zhang, Shuyang
The Epidemiology of COVID-19 and MS-Related Characteristics in a National Sample of People With MS in China
title The Epidemiology of COVID-19 and MS-Related Characteristics in a National Sample of People With MS in China
title_full The Epidemiology of COVID-19 and MS-Related Characteristics in a National Sample of People With MS in China
title_fullStr The Epidemiology of COVID-19 and MS-Related Characteristics in a National Sample of People With MS in China
title_full_unstemmed The Epidemiology of COVID-19 and MS-Related Characteristics in a National Sample of People With MS in China
title_short The Epidemiology of COVID-19 and MS-Related Characteristics in a National Sample of People With MS in China
title_sort epidemiology of covid-19 and ms-related characteristics in a national sample of people with ms in china
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193356/
https://www.ncbi.nlm.nih.gov/pubmed/34122322
http://dx.doi.org/10.3389/fneur.2021.682729
work_keys_str_mv AT zhangyao theepidemiologyofcovid19andmsrelatedcharacteristicsinanationalsampleofpeoplewithmsinchina
AT yinhexiang theepidemiologyofcovid19andmsrelatedcharacteristicsinanationalsampleofpeoplewithmsinchina
AT xuyan theepidemiologyofcovid19andmsrelatedcharacteristicsinanationalsampleofpeoplewithmsinchina
AT xutao theepidemiologyofcovid19andmsrelatedcharacteristicsinanationalsampleofpeoplewithmsinchina
AT pengbin theepidemiologyofcovid19andmsrelatedcharacteristicsinanationalsampleofpeoplewithmsinchina
AT cuiliying theepidemiologyofcovid19andmsrelatedcharacteristicsinanationalsampleofpeoplewithmsinchina
AT zhangshuyang theepidemiologyofcovid19andmsrelatedcharacteristicsinanationalsampleofpeoplewithmsinchina
AT zhangyao epidemiologyofcovid19andmsrelatedcharacteristicsinanationalsampleofpeoplewithmsinchina
AT yinhexiang epidemiologyofcovid19andmsrelatedcharacteristicsinanationalsampleofpeoplewithmsinchina
AT xuyan epidemiologyofcovid19andmsrelatedcharacteristicsinanationalsampleofpeoplewithmsinchina
AT xutao epidemiologyofcovid19andmsrelatedcharacteristicsinanationalsampleofpeoplewithmsinchina
AT pengbin epidemiologyofcovid19andmsrelatedcharacteristicsinanationalsampleofpeoplewithmsinchina
AT cuiliying epidemiologyofcovid19andmsrelatedcharacteristicsinanationalsampleofpeoplewithmsinchina
AT zhangshuyang epidemiologyofcovid19andmsrelatedcharacteristicsinanationalsampleofpeoplewithmsinchina